Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jul 18;7(7):CD011694.
doi: 10.1002/14651858.CD011694.pub2.

Cannabinoids for fibromyalgia

Brian Walitt  1 , Petra Klose, Mary-Ann Fitzcharles, Tudor Phillips, Winfried Häuser
Affiliations
Meta-Analysis

Cannabinoids for fibromyalgia

Brian Walitt et al. Cochrane Database Syst Rev. .

Abstract

Background: This review is one of a series on drugs used to treat fibromyalgia. Fibromyalgia is a clinically well-defined chronic condition of unknown aetiology characterised by chronic widespread pain that often co-exists with sleep problems and fatigue affecting approximately 2% of the general population. People often report high disability levels and poor health-related quality of life (HRQoL). Drug therapy focuses on reducing key symptoms and disability, and improving HRQoL. Cannabis has been used for millennia to reduce pain and other somatic and psychological symptoms.

Objectives: To assess the efficacy, tolerability and safety of cannabinoids for fibromyalgia symptoms in adults.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE to April 2016, together with reference lists of retrieved papers and reviews, three clinical trial registries, and contact with trial authors.

Selection criteria: We selected randomised controlled trials of at least four weeks' duration of any formulation of cannabis products used for the treatment of adults with fibromyalgia.

Data collection and analysis: Two review authors independently extracted the data of all included studies and assessed risk of bias. We resolved discrepancies by discussion. We performed analysis using three tiers of evidence. First tier evidence was derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for drop-outs; at least 200 participants in the comparison, eight to 12 weeks' duration, parallel design), second tier evidence from data that did not meet one or more of these criteria and were considered at some risk of bias but with adequate numbers (i.e. data from at least 200 participants) in the comparison, and third tier evidence from data involving small numbers of participants that were considered very likely to be biased or used outcomes of limited clinical utility, or both. We assessed the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation).

Main results: We included two studies with 72 participants. Overall, the two studies were at moderate risk of bias. The evidence was derived from group mean data and completer analysis (very low quality evidence overall). We rated the quality of all outcomes according to GRADE as very low due to indirectness, imprecision and potential reporting bias.The primary outcomes in our review were participant-reported pain relief of 50% or greater, Patient Global Impression of Change (PGIC) much or very much improved, withdrawal due to adverse events (tolerability) and serious adverse events (safety). Nabilone was compared to placebo and to amitriptyline in one study each. Study sizes were 32 and 40 participants. One study used a cross-over design and one used a parallel group design; study duration was four or six weeks. Both studies used nabilone, a synthetic cannabinoid, with a bedtime dosage of 1 mg/day. No study reported the proportion of participants experiencing at least 30% or 50% pain relief or who were very much improved. No study provided first or second tier (high to moderate quality) evidence for an outcome of efficacy, tolerability and safety. Third tier (very low quality) evidence indicated greater reduction of pain and limitations of HRQoL compared to placebo in one study. There were no significant differences to placebo noted for fatigue and depression (very low quality evidence). Third tier evidence indicated better effects of nabilone on sleep than amitriptyline (very low quality evidence). There were no significant differences between the two drugs noted for pain, mood and HRQoL (very low quality evidence). More participants dropped out due to adverse events in the nabilone groups (4/52 participants) than in the control groups (1/20 in placebo and 0/32 in amitriptyline group). The most frequent adverse events were dizziness, nausea, dry mouth and drowsiness (six participants with nabilone). Neither study reported serious adverse events during the period of both studies. We planned to create a GRADE 'Summary of findings' table, but due to the scarcity of data we were unable to do this. We found no relevant study with herbal cannabis, plant-based cannabinoids or synthetic cannabinoids other than nabilone in fibromyalgia.

Authors' conclusions: We found no convincing, unbiased, high quality evidence suggesting that nabilone is of value in treating people with fibromyalgia. The tolerability of nabilone was low in people with fibromyalgia.

PubMed Disclaimer

Conflict of interest statement

BW: none known; BW is a pain physician who treats people with fibromyalgia.

PK: none known.

MAF is a rheumatologist and pain physician who treats people with fibromyalgia. She is the head of the steering committee of the Canadian guideline on fibromyalgia. She has received:

  1. Consulting fees from AMGEN (one each in 2013, 2015, two in 2014) and Bristol‐Myers Squibb Canada (one in 2014);

  2. Speaking/education fees from Janssen (one in 2014), Johnson & Johnson (one each in 2013, 2014), UCB Canada (one in 2015), Valeant (two in 2013), Pfizer (one in 2013) and Lilly (two in 2013, three in 2014);

  3. In clinic training for ABBVIE staff (one each in 2014, 2015);

  4. AD Board honoraria from Janssen (one in 2014), Pfizer (one in 2013), Purdue (one in 2013), Johnson & Johnson (one in 2014).

TP: none known; TP is a specialist pain physician and manages people with fibromyalgia.

WH is a specialist in general internal medicine, psychosomatic medicine and pain medicine, who treats people with fibromyalgia. He is a member of the medical board of the German Fibromyalgia Association. He is the head of the steering committee of the German guideline on fibromyalgia and a member of the steering committee of the European League Against Rheumatism (EULAR) update recommendations on the management of fibromyalgia. He received speaking fees for one educational lecture each from MSD Sharpe & Dohme (2014) and Grünenthal (2015) on pain management.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Skrabek 2008 {published data only}
    1. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. Journal of Pain 2008;9:164-73. - PubMed
Ware 2010 {published data only}
    1. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia & Analgesia 2010;110:604-10. - PubMed

References to studies excluded from this review

NCT00176163 {published and unpublished data}
    1. NCT00176163. Supporting effect of dronabinol on behavioral therapy in fibromyalgia and chronic back pain. clinicaltrials.gov/ct2/show/NCT00176163 (accessed 27 June 2016).
NCT01149018 {published data only}
    1. NCT01149018. Efficacy trial of oral tetrahydrocannabinol in patients with fibromyalgia. clinicaltrials.gov/ct2/show/NCT01149018 (accessed 27 June 2016).

Additional references

Arnold 2013
    1. Arnold LM, Fan J, Russell IJ, Yunus MB, Khan MA, Kushner I, et al. The fibromyalgia family study: a genome-wide linkage scan study. Arthritis and Rheumatism 2013;65:1122-8. - PMC - PubMed
AUREF 2012
    1. PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 22 January 2015).
Balshem 2011
    1. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64:401-6. - PubMed
Bennett 2009
    1. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the Fibromyalgia Impact Questionnaire. Journal of Rheumatology 2009;36:1304-11. - PubMed
Bradley 2009
    1. Bradley LA. Pathophysiology of fibromyalgia. American Journal Medicine 2009;122:S22-30. - PMC - PubMed
Choi 2011
    1. Choi CJ, Knutsen R, Oda K, Fraser GE, Knutsen S. The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study. Journal Pain 2011;11:994-1003. - PMC - PubMed
Clauw 2014
    1. Clauw D. Fibromyalgia: a clinical review. JAMA 2014;311:1547-55. - PubMed
de Vries 2014
    1. Vries M, Rijckevorsel DC, Wilder-Smith OH, Goor H. Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy 2014;15:1525-34. - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
Eich 2012
    1. Eich W, Häuser W, Arnold B, Bernardy K, Brückle W, Eidmann U, et al. Fibromyalgia syndrome: general principles and coordination of clinical care and patient education [in German]. Schmerz 2012;26:268-75. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving crossover trials: methodological issues. International Journal of Epidemiology 2002;31:140-9. - PubMed
Fitzcharles 2013
    1. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research & Management 2013;18:119-26. - PMC - PubMed
Fitzcharles 2014
    1. Fitzcharles MA, Clauw DJ, Ste-Marie PA, Shir Y. The dilemma of medical marijuana use by rheumatology patients. Arthritis Care and Research 2014;66:797-801. - PubMed
Fiz 2011
    1. Fiz J, Durán M, Capellà D, Carbonell J, Farré M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One 2011;6:e18440. - PMC - PubMed
Forseth 1999
    1. Forseth KO, Husby G, Gran JT, Førre O. Prognostic factors for the development of fibromyalgia in women with self reported musculoskeletal pain. Journal of Rheumatology 1999;26:2458-67. - PubMed
Furukawa 2005
    1. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology 2005;29:49-52. - PubMed
GRADEpro GDT 2015 [Computer program]
    1. GRADEpro GDT 2015: GRADEpro Guideline Development Tool. McMaster University, 2015.
Guindon 2009
    1. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS & Neurological Disorders Drug Targets 2009;8:403-21. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hillard 2012
    1. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012;204:207-29. - PMC - PubMed
Hoch 2015
    1. Hoch E, Bonnet U, Thomasisus R, Ganzer F, Havemann-Reinecke U, Preuss UW. Risks associated with the non-medical use of cannabis. Deutsches Arzteblatt International 2015;112:271-8. - PMC - PubMed
Häuser 2011
    1. Häuser W, Kosseva M, Üceyler N, Klose P, Sommer C. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care and Research 2011;63:808-20. - PubMed
Häuser 2013a
    1. Häuser W, Galek A, Erbslöh-Möller B, Köllner V, Kühn-Becker H, Langhorst J, et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain 2013;154:1216-23. - PubMed
Häuser 2013b
    1. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No: CD010292. [DOI: 10.1002/14651858.CD010292] - DOI - PubMed
Häuser 2014a
    1. Häuser W, Henningsen P. Fibromyalgia syndrome - a somatoform disorder? European Journal Pain 2014;18:1052-9. - PubMed
Häuser 2014b
    1. Häuser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Research & Therapy 2014;16:201. - PMC - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996;17(1):1-12. [DOI: ] - PubMed
Kalant 2001
    1. Kalant H. Medicinal use of cannabis: history and current status. Pain Research & Management 2001;6:80-91. - PubMed
Kalso 2013
    1. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339] - DOI - PubMed
L'Abbé 1987
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33. - PubMed
Lange 2010
    1. Lange M, Petermann F. Influence of depression on fibromyalgia: a systematic review [in German]. Schmerz 2010;24:326-33. - PubMed
Lee 2012
    1. Lee YH, Choi SJ, Ji JD, Song GG. Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatology International 2012;32:417-26. - PubMed
Lee 2013
    1. Lee MC, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 2013;154:124-34. - PMC - PubMed
Long 2009
    1. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proceedings of the National Academy of Science of the United States of America 2009;106:20270-5. - PMC - PubMed
Lunn 2014
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No: CD007115. [DOI: 10.1002/14651858.CD007115.pub3] - DOI - PMC - PubMed
Lynch 2011
    1. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. British Journal of Clinical Pharmacology 2011;72:735-44. - PMC - PubMed
McQuay 1998
    1. McQuay H, Moore R. An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998.
Moore 1998
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7] - DOI - PubMed
Moore 2009
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD007076. [DOI: 10.1002/14651858.CD007076.pub2] - DOI - PMC - PubMed
Moore 2010a
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011] - DOI - PubMed
Moore 2010b
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039] - DOI - PubMed
Moore 2010c
    1. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain 2010;151(3):592-7. [DOI: 10.1016/j.pain.2010.07.013] - DOI - PubMed
Moore 2010d
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805] - DOI - PMC - PubMed
Moore 2011a
    1. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No: CD007938. [DOI: 10.1002/14651858.CD007938.pub2] - DOI - PMC - PubMed
Moore 2011b
    1. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: 10.1016/j.pain.2010.11.030] - DOI - PubMed
Moore 2011c
    1. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569] - DOI - PubMed
Moore 2012a
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No: CD008242. [DOI: 10.1002/14651858.CD008242.pub2] - DOI - PubMed
Moore 2012b
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004] - DOI - PubMed
Moore 2013a
    1. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148] - DOI - PubMed
Moore 2013b
    1. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690] - DOI - PubMed
Moore 2014a
    1. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2014;18(1):67-75. [DOI: 10.1002/j.1532-2149.2013.00341.x] - DOI - PMC - PubMed
Moore 2014b
    1. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94. - PubMed
Mork 2010
    1. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study. Arthritis Care and Research 2010;62:611-7. - PubMed
Mork 2012
    1. Mork PG, Nilsen TI. Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis and Rheumatism 2012;64:281-4. - PubMed
National Pain Foundation 2014
    1. National Pain Foundation. Marijuana rated most effective for treating fibromyalgia, 2014. www.thenationalpainfoundation.org/pain-news.php (accessed 1 April 2015).
Norman 2001
    1. Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Medical Care 2001;39:1039-47. - PubMed
O'Brien 2010
    1. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6-15. [DOI: 10.1111/j.1526-4637.2009.00685.x] - DOI - PubMed
Oaklander 2013
    1. Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013;154:2310-6. - PMC - PubMed
Owens 2015
    1. Owens B. Drug development: the treasure chest. Nature 2015;525:S6-8. - PubMed
Pacher 2006
    1. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 2006;58:389-462. - PMC - PubMed
Queiroz 2013
    1. Queiroz LP. Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports 2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5] - DOI - PubMed
RevMan 2014 [Computer program]
    1. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Russo 2008
    1. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinology Letters 2008;29:192-200. - PubMed
Schaefert 2015
    1. Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Häuser W. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration [in German]. Schmerz 2015;29:47-59. - PubMed
Schley 2006
    1. Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Current Medical Research and Opinion 2006;27:1269-76. - PubMed
Sommer 2012
    1. Sommer C, Häuser W, Burgmer M, Engelhardt R, Gerhold K, Petzke F, et al. Etiology and pathophysiology of fibromyalgia syndrome [in German]. Schmerz 2012;26:259-67. - PubMed
Ste‐Marie 2012
    1. Ste-Marie PA, Fitzcharles MA, Gamsa A, Ware MA, Shir Y. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care & Research (Hoboken) 2012;64:1202-8. - PubMed
Straube 2010
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia - responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150] - DOI - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29] - DOI - PMC - PubMed
van Houdenhove 2004
    1. Van Houdenhove B, Egle UT. Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together. Psychotherapy and Psychosomatics 2004;73:267-75. - PubMed
Volkow 2014
    1. Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. New England Journal of Medicine 2014;371:879. - PubMed
Weber 2009
    1. Weber J, Schley M, Casutt M, Gerber H, Schuepfer G, Rukwied R, et al. Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiology Research and Practice 2009;2009:pii: 827290. - PMC - PubMed
Wiffen 2013
    1. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No: CD010567. [DOI: 10.1002/14651858.CD010567.pub2] - DOI - PMC - PubMed
Wolfe 1990
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33:160-72. - PubMed
Wolfe 2010
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62:600-10. [DOI: 10.1002/acr.20140] - DOI - PubMed
Wolfe 2011
    1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology 2011;38:1113-22. - PubMed
Wolfe 2013
    1. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research 2013;645(5):777-85. [DOI: 10.1002/acr.21931] - DOI - PubMed
Wolfe 2014
    1. Wolfe F, Walitt BT, Häuser W. What is fibromyalgia, how is it diagnosed and what does it really mean? Arthritis Care and Research 2014;66:969-71. [DOI: 10.1002/acr.22207] - DOI - PubMed
Yunus 2008
    1. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Seminars in Arthritis and Rheumatism 2008;37:339-52. - PubMed
Üçeyler 2011
    1. Üçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskeletal Disorders 2011;28:245. - PMC - PubMed
Üçeyler 2013a
    1. Üçeyler N, Zeller D, Kahn AK, Kewenig S, Kittel-Schneider S, Schmid A, et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain 2013;136:e247. - PubMed
Üçeyler 2013b
    1. Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No: CD010782. [DOI: 10.1002/14651858.CD010782] - DOI - PubMed

Publication types